NCT02239926View on ClinicalTrials.gov

Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D

PHASE2/PHASE3TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions

Diarrhea Predominant Irritable Bowel Syndrome

Interventions

DRUG

Ranolazine

On January 31, 2006, ranolazine was approved for use in the United States by the Food and Drug Administration (FDA) for the treatment of chronic angina pectoris.

DRUG

Placebo

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester